Grindeks informs that the first five months of this year have been successful and the company’s sales plan of medicines and active pharmaceutical ingredients has been met.

Grindeks Chairman of the Board Jānis Romanovskis: “Thanks to the marketing and sales activities in all the important markets for Grindeks, the strengthened strategy focused on the introduction and promotion of generics, we look optimistically to the future – this year we will achieve both the profit and turnover plan, thus earning 10 million lats.”

Already a significant turnover growth is achieved in many important markets. Especially good results are in Moldova (+66%), Ukraine (+30%), Latvia (+29%) and Kazakhstan (+18%).

On Grindeks

Grindeks is the leading pharmaceutical company in the Baltic states. Its main fields of action are: research, development, manufacturing and sale of original products, generics and active pharmaceutical ingredients. Grindeks specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups.

Group consists of four subsidiary companies in Latvia, Estonia and Russia, as well representatives and representative offices in fourteen countries. Products of the company are exported to more than 40 countries and its export comprises more than 96% of the total turnover. The main markets are: the Baltic States, Russia and other CIS countries, Japan, the USA. JSC Grindeks shares are listed in the Official List of “Nasdaq OMX Riga”.

Further information:
Laila Kļaviņa
Head of the Communications Department
JSC Grindeks
Phones: (+371) 67083370, (+371) 29256012
Fax: (+371) 67083505
e-mail: laila.klavina@grindeks.lv